Updated:
Sanderling Ventures
Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling demonstrates that significant...
Sanderling Ventures
Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling demonstrates that significant companies are best built in close working partnerships with entrepreneurs. Sanderling's unique approach combines a specialized investment focus with active management and long-term commitment to ensure the highest rates of return for both its entrepreneurs and investors. Sanderling emphasizes early-stage financing and active management of its portfolio companies. Sanderling and its principals play an active role in new ventures by providing seed and early-stage funding, contributing management leadership and administrative support, developing cost-control strategies to extend available dollars, supplying technical and regulatory expertise where needed, and offering the insight and perspective of those who have "done it before."
General information
Firm type
Venture Capital
Year founded
1979
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Mateo
Corporate office
San Mateo, CA, United States
Principals
Fred Middleton
Managing Director
Timothy Mills
Managing Director
Michael Dixon
Principal
Timothy Wollaeger
Managing Director Emeritus
Pierre Beauparlant
Venture Partner
Peter McWilliams
Venture Partner
Benjamin McGraw III
Venture Partner
Paulette Taylor
General Counsel & Principal
Robert G. McNeil
Founding Partner
Sector focus
Frequently asked questions
What is Sanderling Ventures' investment model?
Sanderling practices active biomedical company creation rather than passive financing. Partners routinely take interim executive roles — CEO, CFO, or vice president — inside portfolio companies to set strategy, hire teams, and drive milestones. This operational immersion dates to the firm's 1979 founding and distinguishes it from most venture firms.
Which asset classes does Sanderling Ventures target?
The firm invests exclusively in biomedical sectors: biopharmaceuticals (small molecules, biologics, vaccines, drug-delivery platforms), medical devices, and healthcare IT. It does not manage real estate, debt, or public-equity strategies. The portfolio has historically concentrated on therapeutics and interventional devices.
Does Sanderling Ventures lead rounds, and at what stage does it typically enter?
Sanderling focuses on early-stage financing — seed, start-up, and early growth — and frequently leads or co-leads rounds. Its model favors hands-on involvement, so it often takes the first institutional check and works with founders through development, regulatory filing, and exit.
How does Sanderling source its deals?
Deal flow derives from the firm's relationships with academic medical centers, research institutions, and serial biomedical entrepreneurs. Because partners embed in companies operationally, much sourcing is proprietary — startup ideas often incubate internally before a formal vehicle is formed.
What is Sanderling's posture on co-investment alongside external GPs?
Sanderling co-invests regularly in syndicates, particularly when a company requires phased capital or specialized late-stage clinical investors. The firm's portfolio history shows co-investors including corporate venture arms and crossover public-market funds, especially for companies approaching an IPO or trade sale.
Who are the key decision-makers at Sanderling Ventures?
Managing Directors Fred Middleton and Timothy Mills lead investment decisions. Middleton co-founded the firm in 1979; Mills joined later and shares day-to-day portfolio oversight. The venture partners and principals contribute sector-specific expertise but ultimate allocation authority sits with the managing directors.
Are Sanderling Ventures' returns publicly reported?
No. The firm does not disclose fund-level performance data, IRR, or distributions. Its track record is evidenced by a long list of trade sales and public-company exits — including Regeneron, Pacira, and ViaCyte — rather than externally reported metrics.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: